<DOC>
	<DOCNO>NCT01519869</DOCNO>
	<brief_summary>This prospective study evaluate hypothesis platinum-based neoadjuvant chemotherapy follow interval surgical debulking platinum-based adjuvant chemotherapy associate improved maximal surgical cytoreduction rate , comparable survival , decreased morbidity , increase quality life patient International Federation Gynecologic Oncology stag IIIC IV ovarian , primary peritoneal , fallopian tube cancer compare historical control evaluate hypothesis cancer induce inflammation predictor poor prognosis response therapy group ovarian cancer patient .</brief_summary>
	<brief_title>Trial Chemotherapy Ovarian , Fallopian Tube Peritoneal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Patients biopsy proven stage IIIC/IV epithelial ovarian cancer , primary peritoneal , fallopian tube carcinoma . If core biopsy possible , fineneedle aspirate show adenocarcinoma acceptable set pelvic mass presence metastasis outside pelvis measure least 2 cm , regional lymphnode metastasis proof stage IV disease , ratio CA 125 CEA great 25 . If CA 125 CEA ratio 25 low , barium enema , gastroscopy , mammography must negative . Patients must adequate : Bone marrow function : Absolute neutrophil count ( ANC ) great equal 1,500/μl , equivalent Common Toxicity Criteria Adverse Events v3.0 ( CTCAE ) Grade 1 . This ANC induce support granulocyte colony stimulate factor . Platelets great equal 100,000/μl , CTCAE Grade 01 . Renal function : Creatinine ≤1.5 x institutional upper limit normal ULN ) , CTCAE Grade 1 . Hepatic function : Bilirubin ≤ 1.5 x ULN , CTCAE Grade 1.SGOT alkaline phosphatase ≤ 2.5 x ULN , CTCAE Grade 1 . Neurologic function : Neuropathy ( sensory motor ) less equal CTCAE Grade 1 . Blood coagulation parameter : PT international normalize ratio ( INR ) ≤ 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin management venous thrombosis ) PTT &lt; 1.2 x ULN . Patients must World Health Organization Performance Status ≤2 . Patients must candidate surgery . An approved informed consent must sign patient . Patients receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior radiation localize cancer breast , head neck , skin permit , provide complete three year prior registration , patient remain free recurrent metastatic disease . Patients receive prior chemotherapy abdominal pelvic tumor exclude . Patients may receive prior adjuvant chemotherapy localize breast cancer , provide complete three year prior registration , patient remain free recurrent metastatic disease . Patients know synchronous primary endometrial cancer , past history primary endometrial cancer , exclude , unless follow condition meet : Stage great IA , superficial myometrial invasion , without vascular lymphatic invasion , poorly differentiate subtypes ( include papillary serous , clear cell FIGO Grade 3 lesion ) . With exception nonmelanoma skin cancer specific malignancy note , patient invasive malignancy ( ) evidence cancer present within last five year whose previous cancer treatment contraindicate therapy exclude . Patients acute hepatitis active infection require parenteral antibiotic exclude . Patients World Health Organization Performance Status 3 4 . Patients pregnant nursing . Patients age 18 . Patients pelvic mass size cause pain , subjective symptom intolerable patient . Patients candidate interval surgical debulking secondary significant medical comorbidities .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>peritoneal</keyword>
	<keyword>carcinoma</keyword>
	<keyword>ovarian</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>surgical debulking</keyword>
</DOC>